-
1
-
-
0023859136
-
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
-
DOI 10.1038/332411a0
-
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5. (Pubitemid 18090241)
-
(1988)
Nature
, vol.332
, Issue.6163
, pp. 411-415
-
-
Yanagisawa, M.1
Kurihara, H.2
Kimura, S.3
Tomobe, Y.4
Kobayashi, M.5
Mitsui, Y.6
Goto, K.7
Masaki, T.8
Yazaki, Y.9
-
2
-
-
4644290657
-
Treatment of pulmonary arterial hypertension
-
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
-
(2004)
N Engl J Med
, vol.351
, pp. 1425-36
-
-
Humbert, M.1
Sitbon, O.2
Simonneau, G.3
-
3
-
-
40649084619
-
Endothelin receptor antagonists in pulmonary hypertension
-
Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary hypertension. Eur Respir J 2008;31:407-15.
-
(2008)
Eur Respir J
, vol.31
, pp. 407-415
-
-
Dupuis, J.1
Hoeper, M.M.2
-
4
-
-
70049091002
-
Endothelin receptor antagonists for pulmonary arterial hypertension
-
Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2009;3:CD004434.
-
(2009)
Cochrane Database Syst Rev
, vol.3
-
-
Liu, C.1
Chen, J.2
-
5
-
-
10044258461
-
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology
-
Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
-
(2004)
Eur Heart J
, vol.25
, pp. 2243-78
-
-
Galiè, N.1
Torbicki, A.2
Barst, R.3
-
6
-
-
0024427985
-
The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression
-
Inoue A, Yanangisawa M, Takuwa Y, et al. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989;264:14954-9. (Pubitemid 19237323)
-
(1989)
Journal of Biological Chemistry
, vol.264
, Issue.25
, pp. 14954-14959
-
-
Inoue, A.1
Yanagisawa, M.2
Takuwa, Y.3
Mitsui, Y.4
Kobayashi, M.5
Masaki, T.6
-
7
-
-
33645720494
-
Signalisation cellulaire et physiopathologie de l'hypertension artérielle pulmonaire
-
Dao P, Montani D, Duong-Quy S, et al. Signalisation cellulaire et physiopathologie de l'hypertension artérielle pulmonaire. Rev Mal Respir 2006;23:3S75-83S.
-
(2006)
Rev Mal Respir
, vol.23
-
-
Dao, P.1
Montani, D.2
Duong-Quy, S.3
-
8
-
-
0028793495
-
Endothelin-1 as an autocrine growth factor for endothelial cells
-
Eguchi S, Hirata Y, Imai T, et al. Endothelin-1 as an autocrine growth factor for endothelial cells. J Cardiovasc Pharmacol 1995;26:S279-83.
-
(1995)
J Cardiovasc Pharmacol
, vol.26
-
-
Eguchi, S.1
Hirata, Y.2
Imai, T.3
-
9
-
-
0026034713
-
Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
-
Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.
-
(1991)
Ann Intern Med
, vol.114
, pp. 464-469
-
-
Stewart, D.J.1
Levy, R.D.2
Cernacek, P.3
-
10
-
-
0035818267
-
Endothelin receptor antagonists in pulmonary hypertension
-
Dupuis J. Endothelin receptor antagonists in pulmonary hypertension. Lancet 2001;358:1113.
-
(2001)
Lancet
, vol.358
, pp. 1113
-
-
Dupuis, J.1
-
11
-
-
15944424291
-
Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide
-
DOI 10.1164/rccm.200403-340OC
-
Migneault A, Sauvageau S, Villeneuve L, et al. Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide. Am J Respir Crit Care Med 2005;171:506-13. (Pubitemid 40444252)
-
(2005)
American Journal of Respiratory and Critical Care Medicine
, vol.171
, Issue.5
, pp. 506-513
-
-
Migneault, A.1
Sauvageau, S.2
Villeneuve, L.3
Thorin, E.4
Fournier, A.5
Leblanc, N.6
Dupuis, J.7
-
12
-
-
0036468709
-
B receptors modulate the proliferation of human pulmonary artery smooth muscle cells
-
Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165: 398-405. (Pubitemid 34118516)
-
(2002)
American Journal of Respiratory and Critical Care Medicine
, vol.165
, Issue.3
, pp. 398-405
-
-
Davie, N.1
Haleen, S.J.2
Upton, P.D.3
Polak, J.M.4
Yacoub, M.H.5
Morrell, N.W.6
Wharton, J.7
-
13
-
-
0027299798
-
Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells
-
Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-73. (Pubitemid 23127334)
-
(1993)
Journal of Clinical Investigation
, vol.91
, Issue.4
, pp. 1367-1373
-
-
Hirata, Y.1
Emori, T.2
Eguchi, S.3
Kanno, K.4
Imai, T.5
Ohta, K.6
Marumo, F.7
-
14
-
-
0029741347
-
Human pulmonary circulation is an important site for both clearance and production of endothelin-1
-
Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site of both clearance and production of endothelin-1. Circulation 1996;94:1578-84. (Pubitemid 26320261)
-
(1996)
Circulation
, vol.94
, Issue.7
, pp. 1578-1584
-
-
Dupuis, J.1
Stewart, D.J.2
Cernacek, P.3
Gosselin, G.4
-
15
-
-
34548151315
-
B receptor interactions
-
DOI 10.1159/000102534
-
Sauvageau S, Thorin E, Caron A, et al. Endothelin-1-induced pulmonary vaso reactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 2007;44:375-81. (Pubitemid 47312658)
-
(2007)
Journal of Vascular Research
, vol.44
, Issue.5
, pp. 375-381
-
-
Sauvageau, S.1
Thorin, E.2
Caron, A.3
Dupuis, J.4
-
16
-
-
2542485410
-
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts
-
DOI 10.1091/mbc.E03-12-0902
-
Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Cell Biol 2004;15:2707-19. (Pubitemid 38691860)
-
(2004)
Molecular Biology of the Cell
, vol.15
, Issue.6
, pp. 2707-2719
-
-
Shi-Wen, X.1
Chen, Y.2
Denton, C.P.3
Eastwood, M.4
Renzoni, E.A.5
Bou-Gharios, G.6
Pearson, J.D.7
Dashwood, M.8
Du Bois, R.M.9
Black, C.M.10
Leask, A.11
Abraham, D.J.12
-
17
-
-
0030883691
-
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease
-
Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997;151:831-41. (Pubitemid 27385615)
-
(1997)
American Journal of Pathology
, vol.151
, Issue.3
, pp. 831-841
-
-
Abraham, D.J.1
Vancheeswaran, R.2
Dashwood, M.R.3
Rajkumar, V.S.4
Pantelides, P.5
Shi-wen, X.6
Du Bois, R.M.7
Black, C.M.8
-
18
-
-
0037022927
-
Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension
-
DOI 10.1161/hc0902.105719
-
Bauer M, Wilkens H, Langer F, et al. Selective up-regulation of endothelin b receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-6. (Pubitemid 34212609)
-
(2002)
Circulation
, vol.105
, Issue.9
, pp. 1034-1036
-
-
Bauer, M.1
Wilkens, H.2
Langer, F.3
Schneider, S.O.4
Lausberg, H.5
Schafers, H.-J.6
-
19
-
-
41149100981
-
Endothéline-1 et sélectivité des antagonistes des récepteurs de l'endothéline 1: to B or not to B?
-
Marie I, Bekri S, Lévesque H. Endothéline-1 et sélectivité des antagonistes des récepteurs de l'endothéline 1: to B or not to B? Rev Med Interne 2008:263-8.
-
(2008)
Rev Med Interne
, pp. 263-268
-
-
Marie, I.1
Bekri, S.2
Lévesque, H.3
-
20
-
-
49749102732
-
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: Does selectivity matter?
-
Opitz CF, Ewert R, Kirch W, et al. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008;29: 1936-48.
-
(2008)
Eur Heart J
, vol.29
, pp. 1936-48
-
-
Opitz, C.F.1
Ewert, R.2
Kirch, W.3
-
21
-
-
25844464249
-
Hypertension artérielle pulmonaire
-
Montani D, Jais X, Sitbon O, et al. Hypertension artérielle pulmonaire. Rev Mal Respi 2005;22:651-66.
-
(2005)
Rev Mal Respi
, vol.22
, pp. 651-666
-
-
Montani, D.1
Jais, X.2
Sitbon, O.3
-
22
-
-
70349634397
-
Guidelines for the disgnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the international Society of Heartband Lung Transplantation (ISHLT)
-
Galié N, Hoeper MM, Humbert M, et al. Guidelines for the disgnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the international Society of Heartband Lung Transplantation (ISHLT). Eur Respir J 2009;34:1219-63.
-
(2009)
Eur Respir J
, vol.34
, pp. 1219-63
-
-
Galié, N.1
Hoeper, M.M.2
Humbert, M.3
-
23
-
-
0030031888
-
A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension
-
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302.
-
(1996)
N Engl J Med
, vol.334
, pp. 296-302
-
-
Barst, R.J.1
Rubin, L.J.2
Long, W.A.3
-
24
-
-
0035818316
-
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
-
DOI 10.1016/S0140-6736(01)06250-X
-
Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23. (Pubitemid 32971843)
-
(2001)
Lancet
, vol.358
, Issue.9288
, pp. 1119-1123
-
-
Channick, R.N.1
Simonneau, G.2
Sitbon, O.3
Robbins, I.M.4
Frost, A.5
Tapson, V.F.6
Badesch, D.B.7
Roux, S.8
Rainisio, M.9
Bodin, F.10
Rubin, L.J.11
-
25
-
-
0037149718
-
Bosentan therapy for pulmonary arterial hypertension
-
DOI 10.1056/NEJMoa012212
-
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension (BREATHE-1). N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.12
, pp. 896-903
-
-
Rubin, L.J.1
Badesch, D.B.2
Barst, R.J.3
Galie, N.4
Black, C.M.5
Keogh, A.6
Pulido, T.7
Frost, A.8
Roux, S.9
Leconte, I.10
Landzberg, M.11
Simonneau, G.12
-
26
-
-
0035986906
-
Bosentan: A dual endothelin receptor antagonist
-
DOI 10.1517/13543784.11.7.991
-
Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002;11:991-1002. (Pubitemid 34732717)
-
(2002)
Expert Opinion on Investigational Drugs
, vol.11
, Issue.7
, pp. 991-1002
-
-
Rubin, L.J.1
Roux, S.2
-
27
-
-
0037214229
-
Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
-
DOI 10.1177/0091270002239701
-
Van Giersbergen PLM, Popescu G, Bodin F, et al. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2003;43:15-22. (Pubitemid 36015438)
-
(2003)
Journal of Clinical Pharmacology
, vol.43
, Issue.1
, pp. 15-22
-
-
Van Giersbergen, P.L.M.1
Popescu, G.2
Bodin, F.3
Dingemanse, J.4
-
29
-
-
0033338133
-
Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin
-
Weber C, Banken L, Birnboeck H, et al. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarine. J Clin Pharmacol 1999;39:847-54. (Pubitemid 30629445)
-
(1999)
Journal of Clinical Pharmacology
, vol.39
, Issue.8
, pp. 847-854
-
-
Weber, C.1
Banken, L.2
Birnboeck, H.3
Schulz, R.4
-
30
-
-
0033035969
-
The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects
-
DOI 10.1046/j.1365-2125.1999.00946.x
-
Weber C, Banken L, Birnboeck H, et al. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 1999;47:701-6. (Pubitemid 29257670)
-
(1999)
British Journal of Clinical Pharmacology
, vol.47
, Issue.6
, pp. 701-706
-
-
Weber, C.1
Banken, L.2
Birnboeck, H.3
Nave, S.4
Schulz, R.5
-
31
-
-
0034814769
-
Risk factors for pulmonary arterial hypertension
-
DOI 10.1016/S0272-5231(05)70284-7
-
Humbert M, Nunes H, Sitbon O, et al. Risk Factors for pulmonary arterial hypertension. Clin Chest Med 2001;22:459-75. (Pubitemid 32912079)
-
(2001)
Clinics in Chest Medicine
, vol.22
, Issue.3
, pp. 459-475
-
-
Humbert, M.1
Nunes, H.2
Sitbon, O.3
Parent, F.4
Herve, P.5
Simonneau, G.6
-
33
-
-
4544383466
-
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
-
DOI 10.1183/09031936.04.00028404
-
Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9. (Pubitemid 39232254)
-
(2004)
European Respiratory Journal
, vol.24
, Issue.3
, pp. 353-359
-
-
Humbert, M.1
Barst, R.J.2
Robbins, I.M.3
Channick, R.N.4
Galie, N.5
Boonstra, A.6
Rubin, L.J.7
Horn, E.M.8
Manes, A.9
Simonneau, G.10
-
34
-
-
0344406959
-
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension
-
DOI 10.1016/S0009-9236(03)00005-5
-
Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in paediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82. (Pubitemid 36403597)
-
(2003)
Clinical Pharmacology and Therapeutics
, vol.73
, Issue.4
, pp. 372-382
-
-
Barst, R.J.1
Ivy, D.2
Dingemanse, J.3
Widlitz, A.4
Schmitt, K.5
Doran, A.6
Bingaman, D.7
Nguyen, N.8
Gaitonde, M.9
Van Giersbergen, P.L.M.10
-
35
-
-
9644302310
-
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
-
DOI 10.1164/rccm.200404-445OC
-
Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care med 2004;170:1212-7. (Pubitemid 39577380)
-
(2004)
American Journal of Respiratory and Critical Care Medicine
, vol.170
, Issue.11
, pp. 1212-1217
-
-
Sitbon, O.1
Gressin, V.2
Speich, R.3
Macdonald, P.S.4
Opravil, M.5
Cooper, D.A.6
Fourme, T.7
Humbert, M.8
Delfraissy, J.-F.9
Simonneau, G.10
-
36
-
-
33746206340
-
Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study
-
DOI 10.1161/CIRCULATIONAHA.106.630715, PII 0000301720060704000012
-
Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind randomised, placebo-controlled study. Circulation 2006;114:48-54. (Pubitemid 44305274)
-
(2006)
Circulation
, vol.114
, Issue.1
, pp. 48-54
-
-
Galie, N.1
Beghetti, M.2
Gatzoulis, M.A.3
Granton, J.4
Berger, R.M.F.5
Lauer, A.6
Chiossi, E.7
Landzberg, M.8
-
37
-
-
45249119855
-
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial
-
DOI 10.1016/S0140-6736(08)60919-8, PII S0140673608609198
-
Galiè N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100. (Pubitemid 351902178)
-
(2008)
The Lancet
, vol.371
, Issue.9630
, pp. 2093-2100
-
-
Galie, N.1
Rubin, L.2
Hoeper, M.3
Jansa, P.4
Al-Hiti, H.5
Meyer, G.6
Chiossi, E.7
Kusic-Pajic, A.8
Simonneau, G.9
-
38
-
-
57449103127
-
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (BENEFiT) a randomised placebo-controlled trial
-
Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group
-
Jaïs X, D'Armini AM, Jansa P, et al. Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (BENEFiT) a randomised placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-34.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 2127-34
-
-
Jaïs, X.1
D'Armini, A.M.2
Jansa, P.3
-
39
-
-
34547558919
-
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
-
DOI 10.1183/09031936.00138706
-
Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44. (Pubitemid 47194187)
-
(2007)
European Respiratory Journal
, vol.30
, Issue.2
, pp. 338-344
-
-
Humbert, M.1
Segal, E.S.2
Kiely, D.G.3
Carlsen, J.4
Schwierin, B.5
Hoeper, M.M.6
-
40
-
-
0037484589
-
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension a 1-year follow-up study
-
DOI 10.1378/chest.124.1.247
-
Sitbon O, Badesch DB, Channick R, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. A 1-year follow-up study. Chest 2003;124:247-54. (Pubitemid 36851359)
-
(2003)
Chest
, vol.124
, Issue.1
, pp. 247-254
-
-
Sitbon, O.1
Badesch, D.B.2
Channick, R.N.3
Frost, A.4
Bobbins, I.M.5
Simonneau, G.6
Tapson, V.F.7
Rubin, L.J.8
-
41
-
-
13844280943
-
Survival with first-line bosentan in patients with primary pulmonary hypertension
-
DOI 10.1183/09031936.05.00054804
-
McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9. (Pubitemid 40246523)
-
(2005)
European Respiratory Journal
, vol.25
, Issue.2
, pp. 244-249
-
-
McLaughlin, V.V.1
Sitbon, O.2
Badesch, D.B.3
Barst, R.J.4
Black, C.5
Galie, N.6
Rainisio, M.7
Simonneau, G.8
Rubin, L.J.9
-
42
-
-
33645243403
-
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary hypertension
-
Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary hypertension. Eur Heart J 2006;27:589-95.
-
(2006)
Eur Heart J
, vol.27
, pp. 589-595
-
-
Provencher, S.1
Sitbon, O.2
Humbert, M.3
-
43
-
-
27744444638
-
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
-
DOI 10.1136/thx.2005.040618
-
Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on intravenous epoprostnol. Thorax 2005;60:1025-30. (Pubitemid 41705471)
-
(2005)
Thorax
, vol.60
, Issue.12
, pp. 1025-1030
-
-
Sitbon, O.1
McLaughlin, V.V.2
Badesch, D.B.3
Barst, R.J.4
Black, C.5
Galie, N.6
Humbert, M.7
Rainisio, M.8
Rubin, L.J.9
Simonneau, G.10
-
44
-
-
34250870730
-
Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines
-
DOI 10.1378/chest.06-2674
-
Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice Guidelines. Chest 2007;131: 1917-28. (Pubitemid 46981654)
-
(2007)
Chest
, vol.131
, Issue.6
, pp. 1917-1928
-
-
Badesch, D.B.1
Abman, S.H.2
Simonneau, G.3
Rubin, L.J.4
McLaughlin, V.V.5
-
45
-
-
33750344748
-
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions
-
DOI 10.1136/ard.2005.048967
-
Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40. (Pubitemid 44620443)
-
(2006)
Annals of the Rheumatic Diseases
, vol.65
, Issue.10
, pp. 1336-1340
-
-
Denton, C.P.1
Humbert, M.2
Rubin, L.3
Black, C.M.4
-
46
-
-
0142187600
-
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach
-
DOI 10.1136/ard.62.11.1088
-
Mukerjee D, StGeorges D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93. (Pubitemid 37323574)
-
(2003)
Annals of the Rheumatic Diseases
, vol.62
, Issue.11
, pp. 1088-1093
-
-
Mukerjee, D.1
St George, D.2
Coleiro, B.3
Knight, C.4
Denton, C.P.5
Davar, J.6
Black, C.M.7
Coghlan, J.G.8
-
47
-
-
0037331116
-
Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
-
DOI 10.1378/chest.123.2.344
-
Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50. (Pubitemid 36269414)
-
(2003)
Chest
, vol.123
, Issue.2
, pp. 344-350
-
-
Kawut, S.M.1
Taichman, D.B.2
Archer-Chicko, C.L.3
Palevsky, H.I.4
Kimmel, S.E.5
-
48
-
-
50249155984
-
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue disease
-
Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue disease. Ann Rheum Dis 2008;67:1222-8.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1222-1228
-
-
Denton, C.P.1
Pope, J.E.2
Peter, H.H.3
-
49
-
-
14744304820
-
Bosentan therapy for portopulmonary hypertension
-
DOI 10.1183/09031936.05.00080804
-
Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-8. (Pubitemid 40331181)
-
(2005)
European Respiratory Journal
, vol.25
, Issue.3
, pp. 502-508
-
-
Hoeper, M.M.1
Halank, M.2
Marx, C.3
Hoeffken, G.4
Seyfarth, H.J.5
Schauer, J.6
Niedermeyer, J.7
Winkler, J.8
-
50
-
-
34247891650
-
Hypertension pulmonaire postembolique
-
DOI 10.1016/S0761-8425(07)91572-7
-
Jais X, Dartevelle P, Parent F, et al. Hypertension pulmonaire postembolique. Rev Mal Respir 2007;24:497-508. (Pubitemid 46697454)
-
(2007)
Revue des Maladies Respiratoires
, vol.24
, Issue.4
, pp. 497-508
-
-
Jais, X.1
Dartevelle, P.2
Parent, F.3
Sitbon, O.4
Humbert, M.5
Fadel, E.6
Mussot, S.7
Cabrol, S.8
Le Pavec, J.9
Sztrymf, B.10
Tcherakian, C.11
Musset, D.12
Maitre, S.13
Simonneau, G.14
-
51
-
-
34247863796
-
Hypertension pulmonaire des affections respiratoires chroniques
-
DOI 10.1016/S0761-8425(07)91573-9
-
Chaouat A, Canuet M, Gomez E, et al. Hypertension pulmonaire des affections respiratoires chroniques. Rev Mal Respir 2007;24:509-21. (Pubitemid 46697455)
-
(2007)
Revue des Maladies Respiratoires
, vol.24
, Issue.4
, pp. 509-521
-
-
Chaouat, A.1
Canuet, M.2
Gomez, E.3
Chabot, F.4
Weitzenblum, E.5
-
52
-
-
33847368988
-
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
-
DOI 10.1183/09031936.06.00057906
-
Hoeper MM, leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28: 691-4. (Pubitemid 46331988)
-
(2006)
European Respiratory Journal
, vol.28
, Issue.4
, pp. 691-694
-
-
Hoeper, M.M.1
Leuchte, H.2
Halank, M.3
Wilkens, H.4
Meyer, F.J.5
Seyfarth, H.J.6
Wensel, R.7
Ripken, F.8
Bremer, H.9
Kluge, S.10
Hoeffken, G.11
Behr, J.12
-
53
-
-
33845526777
-
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
-
DOI 10.1164/rccm.200603-358OC
-
McLaughlin VV, Oudiz RJ, Frost A, et al. Randomised study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63. (Pubitemid 44924827)
-
(2006)
American Journal of Respiratory and Critical Care Medicine
, vol.174
, Issue.11
, pp. 1257-1263
-
-
McLaughlin, V.V.1
Oudiz, R.J.2
Frost, A.3
Tapson, V.F.4
Murali, S.5
Channick, R.N.6
Badesch, D.B.7
Barst, R.J.8
Hsu, H.H.9
Rubin, L.J.10
-
54
-
-
70149121675
-
Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: Results of the COMPASS-1 study
-
Gruenig E, Michelakis E, Vachiéry JL, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009;49:1343-52.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 1343-52
-
-
Gruenig, E.1
Michelakis, E.2
Vachiéry, J.L.3
-
56
-
-
38049089932
-
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
-
Burgess G, Hoogkamer H, Collins L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50.
-
(2008)
Eur J Clin Pharmacol
, vol.64
, pp. 43-50
-
-
Burgess, G.1
Hoogkamer, H.2
Collins, L.3
-
57
-
-
44949089427
-
Ambrisentan for the management of pulmonary arterial hypertension
-
DOI 10.1016/j.clinthera.2008.05.005, PII S0149291808001756
-
Cheng JWM. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008;30:825-33. (Pubitemid 351802283)
-
(2008)
Clinical Therapeutics
, vol.30
, Issue.5
, pp. 825-833
-
-
Cheng, J.W.M.1
-
58
-
-
34249854139
-
A review of pulmonary arterial hypertension: Role of ambrisentan
-
Barst RJ. A review of pulmonary hypertension: role of ambrisentan. Vasc Health Risk Mana 2007;3:11-22. (Pubitemid 46860713)
-
(2007)
Vascular Health and Risk Management
, vol.3
, Issue.1
, pp. 11-22
-
-
Barst, R.J.1
-
59
-
-
34249852488
-
Non clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil
-
Dufton C, Gerber MJ, Yin O. Non clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest 2006;130:254S.
-
(2006)
Chest
, vol.130
-
-
Dufton, C.1
Gerber, M.J.2
Yin, O.3
-
60
-
-
34249855849
-
Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin
-
Gerber MJ, Dufton C, Pentikis H. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest 2006;130:256S.
-
(2006)
Chest
, vol.130
-
-
Gerber, M.J.1
Dufton, C.2
Pentikis, H.3
-
61
-
-
22844436819
-
Ambrisentan therapy for pulmonary arterial hypertension
-
DOI 10.1016/j.jacc.2005.04.050, PII S0735109705010478
-
Galiè N, Badesch DB, Oudiz RJ, et al. Ambrisentan therapy of pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35. (Pubitemid 41040298)
-
(2005)
Journal of the American College of Cardiology
, vol.46
, Issue.3
, pp. 529-535
-
-
Galie, N.1
Badesch, D.2
Oudiz, R.3
Simonneau, G.4
McGoon, M.D.5
Keogh, A.M.6
Frost, A.E.7
Zwicke, D.8
Naeije, R.9
Shapiro, S.10
Olschewski, H.11
Rubin, L.J.12
-
62
-
-
46449124591
-
Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomised, double-blind, placebo-controlledm multicenter efficacy (ARIES) study 1 and 2
-
0-10
-
Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomised, double-blind, placebo-controlledm multicenter efficacy (ARIES) study 1 and 2. Circulation 2008;117: 0-10.
-
(2008)
Circulation
, vol.117
-
-
Galiè, N.1
Olschewski, H.2
Oudiz, R.J.3
-
63
-
-
41149113972
-
La prise en charge thérapeutique de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothéline en 2008
-
Cacoub P, Amoura Z, Langleben D. La prise en charge thérapeutique de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothéline en 2008. Rev Med Int 2008;29:283-9.
-
(2008)
Rev Med Int
, vol.29
, pp. 283-289
-
-
Cacoub, P.1
Amoura, Z.2
Langleben, D.3
-
64
-
-
0030943903
-
Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist
-
DOI 10.1021/jm9700068
-
Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997;40:1690-7. (Pubitemid 27231471)
-
(1997)
Journal of Medicinal Chemistry
, vol.40
, Issue.11
, pp. 1690-1697
-
-
Wu, C.1
Chan, M.F.2
Stavros, F.3
Raju, B.4
Okun, I.5
Mong, S.6
Keller, K.M.7
Brock, T.8
Kogan, T.P.9
Dixon, R.A.F.10
-
65
-
-
36849025519
-
The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment
-
DOI 10.1111/j.1365-2125.2007.02979.x
-
Dhaun N, Melville V, Kramer W, et al. The pharmacokinetic profile of sitaxentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. Br J Clin Pharmacol 2007;64:733-7. (Pubitemid 350222060)
-
(2007)
British Journal of Clinical Pharmacology
, vol.64
, Issue.6
, pp. 733-737
-
-
Dhaun, N.1
Melville, V.2
Kramer, W.3
Stavros, F.4
Coyne, T.5
Swan, S.6
Goddard, J.7
Webb, D.J.8
-
66
-
-
0036283401
-
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study
-
DOI 10.1378/chest.121.6.1860
-
Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxentan, an oral endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest 2002;121:1860-8. (Pubitemid 34634407)
-
(2002)
Chest
, vol.121
, Issue.6
, pp. 1860-1868
-
-
Barst, R.J.1
Rich, S.2
Widlitz, A.3
Horn, E.M.4
McLaughlin, V.5
McFarlin, J.6
-
67
-
-
33646255654
-
Treatment of pulmonary arterial hypertension wtih the selective endothelin-receptor antagonist sitaxsentan
-
Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension wtih the selective endothelin-receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 2049-56
-
-
Barst, R.J.1
Langleben, D.2
Badesch, D.3
-
68
-
-
33645047236
-
Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxentan
-
Coyne T, Dixon R. Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxentan. Chest 2005;128:366S.
-
(2005)
Chest
, vol.128
-
-
Coyne, T.1
Dixon, R.2
-
69
-
-
10744230817
-
Sitaxsentan therapy for pulmonary arterial hypertension
-
Barst RJ, Langleben D, Frost A, et al. Sitaxentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7. (Pubitemid 38187114)
-
(2004)
American Journal of Respiratory and Critical Care Medicine
, vol.169
, Issue.4
, pp. 441-447
-
-
Barst, R.J.1
Langleben, D.2
Frost, A.3
Horn, E.M.4
Oudiz, R.5
Shapiro, S.6
McLaughlin, V.7
Hill, N.8
Tapson, V.F.9
Robbins, I.M.10
Zwicke, D.11
Duncan, B.12
Dixon, R.A.F.13
Frumkin, L.R.14
-
70
-
-
29244477173
-
Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension
-
DOI 10.1016/j.amjcard.2005.07.129, PII S000291490501698X
-
Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercice testing and six-minute correlations in pulmonary arterial hypertension. Am J Cardiol 2006;97:123-6. (Pubitemid 41828135)
-
(2006)
American Journal of Cardiology
, vol.97
, Issue.1
, pp. 123-126
-
-
Oudiz, R.J.1
Barst, R.J.2
Hansen, J.E.3
Sun, X.-G.4
Garofano, R.5
Wu, X.6
Wasserman, K.7
-
71
-
-
33847317730
-
Chronic treatment of pulmonary arterial hypertension with sitaxentan and bosentan
-
Benza R, Frost A, Girgis R. Chronic treatment of pulmonary arterial hypertension with sitaxentan and bosentan. Proc Am Thorac Soc 2006;3:A729.
-
(2006)
Proc Am Thorac Soc
, vol.3
-
-
Benza, R.1
Frost, A.2
Girgis, R.3
-
72
-
-
34948865560
-
A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
-
DOI 10.1136/ard.2007.069609
-
Girgis RE, Frist AE, Hills NS, et al. Selective endothelin A receptor antagonism with sitaxentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007;66:1467-72. (Pubitemid 350032654)
-
(2007)
Annals of the Rheumatic Diseases
, vol.66
, Issue.11
, pp. 1467-1472
-
-
Girgis, R.E.1
Frost, A.E.2
Hill, N.S.3
Horn, E.M.4
Langleben, D.5
McLaughlin, V.V.6
Oudiz, R.J.7
Robbins, I.M.8
Seibold, J.R.9
Shapiro, S.10
Tapson, V.F.11
Barst, R.J.12
-
73
-
-
33846247928
-
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing Bosentan
-
DOI 10.1016/j.healun.2006.10.019, PII S1053249806007741
-
Benza RL, Mehta S, Keogh A, et al. Sitaxentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007;26:63-9. (Pubitemid 46096748)
-
(2007)
Journal of Heart and Lung Transplantation
, vol.26
, Issue.1
, pp. 63-69
-
-
Benza, R.L.1
Mehta, S.2
Keogh, A.3
Lawrence, E.C.4
Oudiz, R.J.5
Barst, R.J.6
-
74
-
-
0033837004
-
Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C
-
DOI 10.1006/jmcc.2000.1109
-
Piacentini L, Gray M, Honbo NY, et al. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol 2000;32:565-76. (Pubitemid 30658926)
-
(2000)
Journal of Molecular and Cellular Cardiology
, vol.32
, Issue.4
, pp. 565-576
-
-
Piacentini, L.1
Gray, M.2
Honbo, N.Y.3
Chentoufi, J.4
Bergman, M.5
Karliner, J.S.6
-
75
-
-
2942541475
-
Cellular and molecular pathobiology of pulmonary arterial hypertension
-
Humbert M, Morel NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13-24.
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 13-24
-
-
Humbert, M.1
Morel, N.W.2
Archer, S.L.3
-
76
-
-
35648934472
-
Selective and mixed endothelin receptor antagonism in cardiovascular disease
-
DOI 10.1016/j.tips.2007.10.002, PII S016561470700226X
-
Dhaun N, Pollock DM, Goddard J, et al. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007;28:573-9. (Pubitemid 350026612)
-
(2007)
Trends in Pharmacological Sciences
, vol.28
, Issue.11
, pp. 573-579
-
-
Dhaun, N.1
Pollock, D.M.2
Goddard, J.3
Webb, D.J.4
-
77
-
-
0025836185
-
Endothelin, an endothelial-dependant vasoconstrictor in scleroderma. Enhanced production and profibrotic action
-
Kahaleh MB. Endothelin, an endothelial-dependant vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
-
(1991)
Arthritis Rheum
, vol.34
, pp. 978-983
-
-
Kahaleh, M.B.1
-
78
-
-
0028074746
-
Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis
-
Kawaguchi Y, Suzuki H, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerois. Ann Rheum Dis 1994;53:506-10. (Pubitemid 24256979)
-
(1994)
Annals of the Rheumatic Diseases
, vol.53
, Issue.8
, pp. 506-510
-
-
Kawaguchi, Y.1
Suzuki, K.2
Hara, M.3
Hidaka, T.4
Ishizuka, T.5
Kawagoe, M.6
Nakamura, H.7
-
79
-
-
0028520783
-
Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro
-
Cambrey AD, Harrison NK, Dawes KE, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Moll Biol 1994;11:439-45.
-
(1994)
Am J Respir Cell Moll Biol
, vol.11
, pp. 439-445
-
-
Cambrey, A.D.1
Harrison, N.K.2
Dawes, K.E.3
-
80
-
-
0031629184
-
Endothelins: Effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts
-
Xu S, Denton CP, Holmes A, et al. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998;31:S360-3. (Pubitemid 128709951)
-
(1998)
Journal of Cardiovascular Pharmacology
, vol.31
, Issue.SUPPL. 1
-
-
Xu, S.-W.1
Denton, C.P.2
Holmes, A.3
Dashwood, M.R.4
Abraham, D.J.5
Black, C.M.6
-
81
-
-
85008987259
-
International multidisciplinary consensus classification of the idiopathic interstitial pneumonias
-
American Thoracic Society/European Respiratory Society
-
American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;65:277-304.
-
(2002)
Am J Respir Crit Care Med
, vol.65
, pp. 277-304
-
-
-
84
-
-
0037137109
-
Traitement de la fibrose pulmonaire
-
Cottin V. Traitement de la fibrose pulmonaire. Presse Med 2002;31:1613-23. (Pubitemid 36292106)
-
(2002)
Presse Medicale
, vol.31
, Issue.34
, pp. 1613-1623
-
-
Cottin, V.1
-
85
-
-
51549101867
-
Interstitial lung disease guideline: The British Thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society
-
British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of care Committee; Thoracic Society of Australia, New Zealand Thoracic Society; Irish Thoracic Society
-
Wells AU, Hirani N, British Thoracic Society, Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of care Committee; Thoracic Society of Australia, New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63:v1-58.
-
(2008)
Thorax
, vol.63
-
-
Wells, A.U.1
Hirani, N.2
-
86
-
-
0345824715
-
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
-
DOI 10.1056/NEJMoa030511
-
Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33. (Pubitemid 38056223)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.2
, pp. 125-133
-
-
Raghu, G.1
Brown, K.K.2
Bradford, W.Z.3
Starko, K.4
Noble, P.W.5
Schwartz, D.A.6
King Jr., T.E.7
-
88
-
-
77749324295
-
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebocontrolled trial results
-
Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebocontrolled trial results. Am J Respir Crit Care Med 2010;181:604-10.
-
(2010)
Am J Respir Crit Care Med
, vol.181
, pp. 604-610
-
-
Daniels, C.E.1
Lasky, J.A.2
Limper, A.H.3
-
89
-
-
20944434994
-
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
-
DOI 10.1164/rccm.200404-571OC
-
Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7. (Pubitemid 40616955)
-
(2005)
American Journal of Respiratory and Critical Care Medicine
, vol.171
, Issue.9
, pp. 1040-1047
-
-
Azuma, A.1
Nukiwa, T.2
Tsuboi, E.3
Suga, M.4
Abe, S.5
Nakata, K.6
Taguchi, Y.7
Nagai, S.8
Itoh, H.9
Ohi, M.10
Sato, A.11
Kudoh, S.12
Raghu, G.13
-
90
-
-
0035895243
-
Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy
-
Selman M, King Jr TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134: 136-51. (Pubitemid 32096342)
-
(2001)
Annals of Internal Medicine
, vol.134
, Issue.2
, pp. 136-151
-
-
Selman, M.1
King Jr., T.E.2
Pardo, A.3
-
91
-
-
25444457220
-
Idiopathic pulmonary fibrosis: An epithelial: Fibroblastic cross-talk disorder
-
Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial: fibroblastic cross-talk disorder. Respir Res 2002;3:3-10.
-
(2002)
Respir Res
, vol.3
, pp. 3-10
-
-
Selman, M.1
Pardo, A.2
-
93
-
-
36348938856
-
Bosentan et fibrose pulmonaire
-
DOI 10.1016/S0248-8663(07)80022-1, PII S0248866307800221
-
Cottin V, Cordier JF. Bosentan et fibrose pulmonaire. Rev Med Intern 2007;28:S230-7. (Pubitemid 350148234)
-
(2007)
Revue de Medecine Interne
, vol.28
, Issue.SUPPL. 3
-
-
Cottin, V.1
Cordier, J.-F.2
-
94
-
-
0032825924
-
Effect of endothelin-1 on α-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases
-
DOI 10.1016/S0192-0561(99)00056-9, PII S0192056199000569
-
Shahar I, Fireman E, Topilsky M, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstital lung diseases. Int J Immunopharmacol 1999;21:759-75. (Pubitemid 29472503)
-
(1999)
International Journal of Immunopharmacology
, vol.21
, Issue.11
, pp. 759-775
-
-
Shahar, I.1
Fireman, E.2
Topilsky, M.3
Grief, J.4
Schwarz, Y.5
Kivity, S.6
Ben-Efraim, S.7
Spirer, Z.8
-
95
-
-
2542485410
-
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts
-
DOI 10.1091/mbc.E03-12-0902
-
Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Moll Biol Cell 2004;15: 2707-19. (Pubitemid 38691860)
-
(2004)
Molecular Biology of the Cell
, vol.15
, Issue.6
, pp. 2707-2719
-
-
Shi-Wen, X.1
Chen, Y.2
Denton, C.P.3
Eastwood, M.4
Renzoni, E.A.5
Bou-Gharios, G.6
Pearson, J.D.7
Dashwood, M.8
Du Bois, R.M.9
Black, C.M.10
Leask, A.11
Abraham, D.J.12
-
96
-
-
0030755489
-
Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist
-
Park SH, Saleh D, Giaid A, et al. Increased endothelin-1 in bleomycin-I induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;165:600-8. (Pubitemid 27352001)
-
(1997)
American Journal of Respiratory and Critical Care Medicine
, vol.156
, Issue.I2
, pp. 600-608
-
-
Park, S.-H.1
Saleh, D.2
Giaid, A.3
Michel, R.P.4
-
97
-
-
37849012578
-
BUILD-1: A randomised placebo-controlled trial of Bosentan in idiopathic pulmonary fibrosis
-
King Jr TE, Behr J, Brown KK, et al. BUILD-1: a randomised placebo-controlled trial of Bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
-
(2008)
Am J Respir Crit Care Med
, vol.177
, pp. 75-81
-
-
King Jr., T.E.1
Behr, J.2
Brown, K.K.3
-
98
-
-
54949126557
-
High-resolution computed tomography (HRCT) features correlate with response to bosentan in idiopathic pulmonary fibrosis (IPF): The BUILD-1study
-
Lynch DA, Behr J, Brown KK, et al. High-resolution computed tomography (HRCT) features correlate with response to bosentan in idiopathic pulmonary fibrosis (IPF): the BUILD-1study. Am Thorac Soc Int Conf 2007:A567.
-
(2007)
Am Thorac Soc Int Conf
-
-
Lynch, D.A.1
Behr, J.2
Brown, K.K.3
-
99
-
-
80051566676
-
BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
-
King Jr TE, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-9.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 92-99
-
-
King Jr., T.E.1
Brown, K.K.2
Raghu, G.3
-
100
-
-
33845287938
-
Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): The BUILD-2 study
-
Seibold JR, Black CM, Denton CP, et al. Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): the BUILD-2 study. Proc Am Thorac 2006;3:A243.
-
(2006)
Proc Am Thorac
, vol.3
-
-
Seibold, J.R.1
Black, C.M.2
Denton, C.P.3
-
101
-
-
33744922911
-
Profile of past and current clinical trials involving endothelin receptor antagonists: The novel '-sentan' class of drug
-
Battistini B, Berthaume N, Kelland NF, et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the Novel "-Sentan" class of drug. Exp Biol Med 2006;231:653-95. (Pubitemid 43845510)
-
(2006)
Experimental Biology and Medicine
, vol.231
, Issue.6
, pp. 653-695
-
-
Battistini, B.1
Berthiaume, N.2
Kelland, N.F.3
Webb, D.J.4
Kohan, D.E.5
|